ChromaDex Corp. is an integrated, global nutraceutical company devoted to improving the way people age. ChromaDex scientists partner with leading universities and research institutions worldwide to uncover the full potential of NAD and identify and develop novel, science-based ingredients. Its flagship ingredient, NIAGEN® nicotinamide riboside, sold directly to consumers as TRU NIAGEN®, is backed with clinical and scientific research, as well as extensive IP protection. TRU NIAGEN® is helping the world AGE BETTER®

More »
Stock Quote
Change (%) Stock is Up 0.15 (3.41%)
Refresh quote
Real-Time Level 2 Quote
Recent NewsMore »
04/24/19ChromaDex Furthers TRU NIAGEN® Global Expansion in Canada with WELL Health Technologies
Distribution agreement for Tru Niagen (nicotinamide riboside) in Vancouver area provides access to high-end pharmacies and clinics LOS ANGELES, April 24, 2019 (GLOBE NEWSWIRE) -- ChromaDex Corp. (NASDAQ:CDXC) announced today a new distribution partnership for TRU NIAGEN® with Vancouver-based WELL Health Technologies Corp. (TSX.V: WELL) who intends on distributing TRU NIAGEN® via its partner network of pharmacy and other allied health businesses. According to Orbis Research, the $250 billio... 
Printer Friendly Version
04/15/19ChromaDex Drives Global Expansion Strategy for TRU NIAGEN® with Specialty Retail Launch and Expanded eCommerce Distribution in Canada
ChromaDex flagship Tru Niagen (nicotinamide riboside) product now available in Showcase specialty retail stores in Canada LOS ANGELES, April 15, 2019 (GLOBE NEWSWIRE) -- ChromaDex Corp. (NASDAQ:CDXC) announced today the latest milestone in its global expansion strategy for TRU NIAGEN®, with a strategic deal with specialty retailer Showcase in Toronto, Canada. Tru Niagen is now available in 36 Showcase stores in the greater Toronto area as well as Showcase’s online store. Showcase operates 118... 
Printer Friendly Version
04/09/19New Study Deepens Research Into the Potential Cardiovascular Health Benefits of Supplementation with Nicotinamide Riboside (NR)
Data published in the Journal of American College of Cardiology shows that this novel form of vitamin B3 helps maintain mitochondrial function in an animal model by stimulating a cellular repair pathway; preliminary human data also support future testing of NR in connection with cardiac health LOS ANGELES--(BUSINESS WIRE)--Apr. 9, 2019-- ChromaDex Corp. (NASDAQ:CDXC) today reported that results of a new preclinical study showed that sup... 
Printer Friendly Version
What's New
2019 Proxy Statement PDF
March 2019 Investor Presentation PDF
Q4 2018 Earnings Presentation  PDF
2018 Annual Report on Form 10K  PDF
December 2018 Investor Presentation PDF
ChromaDex Investor FAQs Third Quarter 2018 PDF
Q3 2018 Earnings Presentation PDF
September 2018 Investor Presentation PDF
July 2018 Investor Presentation PDF
Get help downloading or viewing the above file types
Receive E-mail AlertsE-mail Alert Icon
Sign up to receive e-mail alerts whenever Chromadex Corp posts new information to the site. Just enter your e-mail address and click Submit.
Data provided by Nasdaq. Minimum 15 minutes delayed.